Opus Genetics (IRD) Short term Debt (2021 - 2022)
Opus Genetics (IRD) posted quarterly Short term Debt of $215000.0 for Q1 2022, down 60.04% quarter-over-quarter from $538000.0 in Q4 2021.
Powered by 
Analysis
Opus Genetics (IRD) Short term Debt (2021 - 2022) Analysis & Trends
Opus Genetics (IRD) has reported Short term Debt for 2 consecutive years, with $215000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Short term Debt changed N/A year-over-year to $215000.0; the TTM figure through Mar 2022 stood at $215000.0 (changed N/A YoY), while the FY2021 annual figure was $538000.0, changed N/A from the prior year.
- Short term Debt fell to $215000.0 in Q1 2022 per IRD's latest filing, from $538000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $538000.0 in Q4 2021 and bottomed at $215000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |